Cement enterprises will keep improving and continue to grasp the details when they hold another benchmarking meeting.
Release time:
2022-08-04
7# January 20 , the group company organized its subordinate cement enterprises to hold the second quarter benchmarking meeting. In terms of production technical indicators and cost control, benchmarking management is carried out, focusing on key parts and key links, tapping the potential for improvement, and creating a good atmosphere for mutual reference and common growth. The second quarter benchmarking of
was originally scheduled to be held at the group company's business analysis meeting in the first half of the year, but due to time constraints, "second half " was added on 20 . Although there was such a small twists and turns, everyone's enthusiasm did not decay at all. The technical leaders of the three cement companies in Daye, Yunnan, and Guizhou conducted detailed exchanges and comparisons on every key technical indicator in cement production. From the power consumption of the single machine of the crusher, to the load of the roller press and the fineness of the grinding cement ... , many indicators are compared in turn to find out their own shortcomings and analyze the reasons, details such as the air pressure of "pick " to 0.09mpa kiln system, the unit power consumption of 0.1 degrees, and whether the roller surface texture of the roller press is rhombic or horizontal should be discussed repeatedly, which fully reflects the attitude of keeping improving. In addition to exchanging experiences with each other, each unit also shares the solutions to problems encountered and changes that have been verified to be invalid with colleagues, so as to prevent brother units from taking the wrong path.
Due to too much discussion from each unit, the original half-day meeting time in the morning passed quickly. Even if it was finally extended to 12 : 30, which delayed lunch, there were still many topics that did not finish "Chat " , and only some content tips could be made, after the meeting, do "point-to-point " communication and sharing. Yu Jianhong, general manager of
Group Company, said that the benchmarking meeting is a good communication platform. Only when there is comparison can we better find out the deficiencies, and only when there is comparison can we see clearly the room for improvement in our work. The Group has always focused on quality management, while product quality control focuses on the source, and raw materials affect every aspect of subsequent production. From the planning of mining to the use of raw materials, each plant should be based on the difference in raw materials, the pursuit of comprehensive cost optimization, to meet the stable operation of the kiln, high-performance output. In terms of equipment and process management, key equipment and process key points shall be controlled by sections in addition to daily inspection and maintenance.
Since the group company launched the cement enterprise benchmarking meeting, many experiences and methods have become the common measures of the three cement enterprises, which have achieved remarkable results in reducing costs and improving benefits. In the future, the benchmarking meeting will be held regularly every quarter to help cement enterprises "compare, learn, catch up, help and surpass " , speed up the filling of various short boards, solve the problems existing in production, and promote the effective improvement of enterprise management ability and operation level. (Reporter Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page